Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:8618 |
| Name | oral cavity cancer |
| Definition | A gastrointestinal system cancer that is located_in the oral cavity. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:9049 DOID:9055 DOID:8617 DOID:0050627 |
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| ABL1 G250R ABL1 G251D | Nilotinib | oral cavity cancer | no benefit | detail... |
| CD274 positive | Pembrolizumab | oral cavity cancer | sensitive | detail... |
| CD274 positive | Ipilimumab + Nivolumab | oral cavity cancer | sensitive | detail... |
| MLH1 negative | Pembrolizumab | oral cavity cancer | sensitive | detail... |
| PMS2 negative | Pembrolizumab | oral cavity cancer | sensitive | detail... |
| MSH2 negative | Pembrolizumab | oral cavity cancer | sensitive | detail... |
| MSH6 negative | Pembrolizumab | oral cavity cancer | sensitive | detail... |
| FGFR1 act mut | Erdafitinib | oral cavity cancer | sensitive | detail... |
| FGFR1 fusion | Erdafitinib | oral cavity cancer | sensitive | detail... |
| FGFR2 fusion | Erdafitinib | oral cavity cancer | sensitive | detail... |
| FGFR2 act mut | Erdafitinib | oral cavity cancer | sensitive | detail... |
| FGFR3 act mut | Erdafitinib | oral cavity cancer | sensitive | detail... |
| FGFR3 fusion | Erdafitinib | oral cavity cancer | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01218048 | Phase II | Cisplatin Carboplatin Cetuximab | ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT01316757 | Phase II | Carboplatin + Cetuximab + Erlotinib + Paclitaxel | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | Completed | USA | 0 |
| NCT01414426 | Phase II | Vandetanib | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | Completed | USA | 0 |
| NCT01467115 | Phase II | Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab | INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER | Completed | USA | 0 |
| NCT01790204 | Phase Ib/II | Phenethyl isothiocyanate | A Study of the Effects of PEITC on Oral Cells With Mutant p53 | Completed | USA | 0 |
| NCT02124850 | Phase I | Cetuximab | A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337 | Terminated | USA | 0 |
| NCT02262741 | Phase I | Tremelimumab Durvalumab | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer | Completed | USA | CAN | 0 |
| NCT02449681 | Phase II | TH-4000 | Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS | Terminated | USA | AUS | 0 |
| NCT02643550 | Phase Ib/II | Cetuximab + Monalizumab | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | FRA | 0 |
| NCT02734537 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Recruiting | USA | 0 |
| NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT03040999 | Phase III | Cisplatin + Pembrolizumab Cisplatin | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | Completed | USA | TUR | POL | NZL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 4 |
| NCT03179956 | Phase I | Ribociclib | Impact of Ribociclib on Head and Neck Squamous Cell Cancer | Terminated | USA | 0 |
| NCT03389477 | Phase II | Cisplatin + Palbociclib Cetuximab + Palbociclib | Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03529422 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | Active, not recruiting | USA | 0 |
| NCT03539198 | Phase 0 | Nivolumab | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | Terminated | USA | 0 |
| NCT03765918 | Phase III | Pembrolizumab Cisplatin + Pembrolizumab Cisplatin | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | Active, not recruiting | USA | POL | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT04080804 | Phase II | Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | Recruiting | USA | 0 |
| NCT04128696 | Phase III | Pembrolizumab GSK3359609 + Pembrolizumab | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) | Terminated | USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | AUS | ARG | 7 |
| NCT04428151 | Phase II | Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | Active, not recruiting | USA | ROU | NOR | ISR | GBR | FRA | ESP | DNK | CAN | BRA | AUS | 4 |
| NCT04428333 | Phase III | Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | SWE | ROU | POL | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUS | ARG | 3 |
| NCT04477759 | Phase I | Atezolizumab | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) | Active, not recruiting | USA | 0 |
| NCT04815720 | Phase Ib/II | Pembrolizumab + Pepinemab | Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84) | Completed | USA | 0 |
| NCT04830592 | Phase I | NG-641 NG-641 + Pembrolizumab | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT) | Completed | GBR | 0 |
| NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
| NCT04969861 | Phase II | NKTR-214 + Pembrolizumab Pembrolizumab | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | Terminated | USA | ITA | GRC | AUT | 0 |
| NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | GBR | ESP | BEL | AUT | 0 |
| NCT05061420 | Phase II | Cetuximab + Pembrolizumab + THOR-707 Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CAN | ARG | 3 |
| NCT05172258 | Phase II | Ipatasertib + Pembrolizumab Pembrolizumab | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | Recruiting | USA | 0 |
| NCT05329532 | Phase Ib/II | Modi-1 Modi-1 + Pembrolizumab | Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) | Recruiting | GBR | 0 |
| NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
| NCT05366166 | Phase II | Cisplatin + Olaparib + Pembrolizumab | Pembrolizumab Plus Olaparib in LA-HNSCC | Recruiting | USA | 0 |
| NCT05376553 | Phase I | Cemiplimab + Cisplatin + Docetaxel | Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Enrolling by invitation | USA | 0 |
| NCT05712356 | Phase II | CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) | Recruiting | USA | ESP | 0 |
| NCT05721755 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + Pembrolizumab | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
| NCT05815927 | Phase III | Pembrolizumab | Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (PROLoNg) | Not yet recruiting | ITA | ESP | CHE | BEL | 0 |
| NCT06557889 | Phase II | Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab | Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (REDUCE) | Recruiting | FRA | 0 |
| NCT06597565 | Phase II | Gemcitabine + Prexasertib | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Recruiting | USA | 0 |
| NCT06640725 | Phase II | Cetuximab + Cisplatin + Docetaxel Carboplatin + Cetuximab + Docetaxel Avelumab + Cetuximab | Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N (TATIANA) | Recruiting | FRA | 0 |
| NCT06788990 | Phase II | Pembrolizumab BCA101 + Pembrolizumab | FORTIFI-HN01: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC (FORTIFI-HN01) | Recruiting | USA | 0 |
| NCT06789172 | Phase I | OKN4395 + Pembrolizumab OKN4395 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients with Solid Tumors (INVOKE) | Recruiting | USA | AUS | 0 |
| NCT06790966 | Phase III | PDS0101 + Pembrolizumab Pembrolizumab | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (VERSATILE-003) | Recruiting | USA | 0 |
| NCT06806852 | Phase I | Pembrolizumab BI 770371 + Cetuximab + Pembrolizumab BI 770371 + Pembrolizumab | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | Not yet recruiting | USA | TUR | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | BRA | BGR | AUS | 7 |
| NCT06856213 | Phase II | Cetuximab Cetuximab + Paclitaxel | Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. (ERBIOTAX) | Not yet recruiting | ESP | 0 |
| NCT06868433 | Phase I | Pembrolizumab + TMV vaccine TMV vaccine | TMV Vaccine Therapy Alone and with Pembrolizumab for the Treatment of Recurrent And/or Metastatic Head and Neck Squamous Cell Cancer | Not yet recruiting | USA | 0 |
| NCT06869473 | Phase II | Avelumab + Cetuximab Paclitaxel | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)>/=1=/<19. (AVEC-119) | Recruiting | ITA | 0 |